APA

Cresswell F. V., Ssebambulidde K., Grint D., Te Brake L., Musabire A., Atherton R. R., Tugume L., Muzoora C., Lukande R., Lamorde M., Aarnoutse R., Meya D., Boulware D. R. & Elliott A. M. (2018). High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). : Wellcome open research.

Chicago

Cresswell Fiona V, Ssebambulidde Kenneth, Grint Daniel, Te Brake Lindsey, Musabire Abdul, Atherton Rachel R, Tugume Lillian, Muzoora Conrad, Lukande Robert, Lamorde Mohammed, Aarnoutse Rob, Meya David, Boulware David R and Elliott Alison M. 2018. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). : Wellcome open research.

Harvard

Cresswell F. V., Ssebambulidde K., Grint D., Te Brake L., Musabire A., Atherton R. R., Tugume L., Muzoora C., Lukande R., Lamorde M., Aarnoutse R., Meya D., Boulware D. R. and Elliott A. M. (2018). High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). : Wellcome open research.

MLA

Cresswell Fiona V, Ssebambulidde Kenneth, Grint Daniel, Te Brake Lindsey, Musabire Abdul, Atherton Rachel R, Tugume Lillian, Muzoora Conrad, Lukande Robert, Lamorde Mohammed, Aarnoutse Rob, Meya David, Boulware David R and Elliott Alison M. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). : Wellcome open research. 2018.